Increasing clinical trials, strategic collaborations, and regulatory support are accelerating the development of NK cell-based therapies. The market is expected to expand further with improvements ...

The research team demonstrated that innate immune cells called Natural Killer (NK) cells that express CD8a on the cell ...

Research and development activities for NK cell therapies are rapidly evolving, backed by significant advancements in immunotherapy-centric cancer treatment approaches. Unlike other immune cells ...

DelveInsight’s Natural Killer (NK)-Cell Lymphoma Pipeline report depicts a robust space with 100+ active players working to develop 140+ pipeline therapies for Natural Killer (NK)-Cell Lymphoma ...

The innate advantages of NK cells mean that CAR-NK cell therapy offers immense potential for the development of allogeneic and scalable products, unlike the primarily autologous nature of CAR-T ...

Logomix is also participating in development collaboration with biotech ... form a strategic partnership to develop gene-edited NK cells and genetic modifications to create next gen designer ...

Along with DF-7001, which is scheduled to start clinical testing next year, Gilead has options on several other TriNKET candidates in early development. NK cell engagers are an emerging ...

Another strategy genetically engineers allogeneic NK cells with chimeric antigen receptors (CARs). Also on the radar is the development of induced pluripotent stem cells (iPSC) that can escape ...

IKAROS and AIOLOS directly regulate AP-1 transcriptional complexes and are essential for NK cell development. Nature Immunology , 2024; DOI: 10.1038/s41590-023-01718-4 Cite This Page : ...

The two companies will collaborate on the development of targeted NK cell and macrophage cells derived from induced pluripotent stem cells (iPSC), cementing a relationship that has already seen ...

The fight against HIV remains a major public health challenge, primarily due to the persistence of viral reservoirs that require lifelong antiretroviral treatment. However, some individuals, known ...

the company said the top priority for spending the proceeds will be on continuing the clinical development of its lead program AlloNK. The non-genetically modified, cryopreserved NK cell therapy ...